| 嵌合抗原受体T细胞免疫疗法治疗多发性骨髓瘤的研究进展 |
| |
| 引用本文： | 刘奕晨,孙志强,郑方. 嵌合抗原受体T细胞免疫疗法治疗多发性骨髓瘤的研究进展[J]. 安徽医药, 2017, 21(6). DOI: 10.3969/j.issn.1009-6469.2017.06.002 |
| |
| 作者姓名： | 刘奕晨 孙志强 郑方 |
| |
| 作者单位： | 贵州医科大学研究生院,贵州 贵阳,550000;贵州医科大学附属医院血液内科, 贵州 贵阳 550000;南方医科大学深圳医院血液内科,广东 深圳 518000;贵州医科大学附属医院血液内科, 贵州 贵阳 550000;贵州医科大学附属白云医院血液内科,贵州 贵阳 550000 |
| |
| 摘 要： | 免疫疗法在恶性肿瘤治疗中的应用正日益受到关注.嵌合抗原受体(CAR)技术是一种新兴的免疫疗法,在血液肿瘤的治疗上具有巨大的潜力.嵌合抗原受体T细胞免疫疗法(CAR-T)可通过特异性识别靶抗原来杀伤骨髓瘤细胞,使治疗复发难治性多发性骨髓瘤成为可能.该文重点对CAR-T在多发性骨髓瘤治疗方面的研究进展作一综述,并对可能作为CAR-T治疗多发性骨髓瘤的靶抗原进行了分析.
|
| 关 键 词： | 嵌合抗原受体 多发性骨髓瘤 免疫治疗 |
The review of application and challenge of CAR-T in the treatment of multiple myeloma |
| |
| LIU Yichen,SUN Zhiqiang,ZHEN Fang. The review of application and challenge of CAR-T in the treatment of multiple myeloma[J]. Anhui Medical and Pharmaceutical Journal, 2017, 21(6). DOI: 10.3969/j.issn.1009-6469.2017.06.002 |
| |
| Authors: | LIU Yichen SUN Zhiqiang ZHEN Fang |
| |
| Abstract: | Application of immunotherapy in malignant tumor has widely been focused.Chimeric antigen receptor is one of the emerging immunotherapy and has enormous potentiality to treat hematologic neoplasms.Chimeric antigen receptor-modified T cells(CAR-T) may contribute to treat multiple myeloma as CAR-T can kill target myeloma cells by means of identifying the target antigen.In this article,the research advances of CAR-T in treating multiple myeloma were reviewed,and the antigens which may be an effective target for CAR-T in eliminating myeloma cells were analyzed. |
| |
| Keywords: | Chimeric antigen receptor Multiple myeloma Immunotherapy |
| 本文献已被 万方数据 等数据库收录！ |
